Project Grant R00HL164888
Award Date
8/1/24
Completion Date
7/31/27
Dollars Obligated
$828K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Bloodworks (ZN56PFWUDQK7)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) totaling $1,276,908 to Bloodworks, a nonprofit organization in Seattle, WA. The grant, titled "Molecular and Translational Studies in Hematologic Disorders," will fund research focused on understanding the mechanisms of disease in von Willebrand disease and sickle cell disease, both of which involve von Willebrand factor. The proposed studies will investigate...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $465,000.00 to Bloodworks (formerly Puget Sound Blood Center and Program) to investigate the mechanisms by which chronic inflammation disrupts autophagy and mitophagy in platelets and red blood cells in sickle cell disease. The research aims to elucidate how inflammation-driven dysfunction of these critical cellular processes...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the role of sickle red blood cells (RBCs) in activating neutrophils and promoting vaso-occlusion in sickle cell disease (SCD). The key objectives of the research are to: 1) delineate the characteristics of sickle RBCs that contribute to neutrophil activation, 2) examine the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) totals $179,280 and runs from September 1, 2024 to August 31, 2026. The grant supports research by The Trustees of the University of Pennsylvania to investigate how early life nutritional stress impacts neutrophil development and function, and how this relates to the severity of sickle cell disease. The research aims to uncover novel...
This Project Grant award, valued at $607,535, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the effects of the breakdown product hemin on the pulmonary endothelium and its contribution to the pulmonary complications of sickle cell disease, including acute chest syndrome and pulmonary hypertension. The research aims to evaluate the specific effects of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $483,852 to The General Hospital Corporation (Massachusetts General Hospital) to develop a high-throughput platform technology to measure the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This new platform will enable the optimization of emerging sickle cell disease...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $265,347 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Functional Fluidics Inc., a minority-owned for-profit company in Detroit, Michigan. The grant supports the development and initial validation of a point-of-care (POC) device to assess red blood cell (RBC) sickling as an indicator of sickle cell disease (SCD) patient condition and treatment monitoring. The proposed "Dynamic Sickling...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $765,622 to develop orally bioavailable protein degraders that target fetal hemoglobin gene repressors. The goal is to elevate fetal hemoglobin levels and prevent erythroid sickling to treat sickle cell disease. The research is a collaborative effort between Yale University and the Children's Hospital of Philadelphia,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to investigate the role of heme-induced complement activation in sickle cell disease (SCD) pregnancy. The $202,366 award, spanning September 1, 2024 to August 31, 2025, will support a study using a mouse model of SCD to characterize the effects of SCD and heme-induced complement activation on pregnancy outcomes (Aim 1), and...